We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use www.guysandstthomasevents.co.uk, remember your settings and improve our services. We also use cookies set by other sites to help us deliver content from their services.
The RBD Symposium explores the diagnosis, treatment, and prognosis of REM Sleep Behavior Disorder, highlighting its link to neurodegeneration. It gathers experts and patient representatives to share research and foster clinical collaboration
Venue:
Governors Hall
Date:
05/12/2025
Location:
St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH
REM sleep behaviour disorder (RBD) is a sleep condition characterised by the presence of dream enactment episodes. The RBD Symposium comprehensively outlines how to identify and treat patients with RBD, and provides insight on the relevant prognostic implications of this sleep condition. This meeting also offers an invaluable opportunity to learn about the current research landscape on RBD and its links with neurodegeneration.
Involving international and national experts in the field, as well as patient representatives, the RBD Symposium will provide a multi-disciplinary setting for clinicians and healthcare professionals to network and share their knowledge.
This event is CPD accredited all delegates attending the conference will receive an electronic certificate of attendance.
Highlights
The intricacies of diagnosing RBD: challenges from a clinical and technical point of view
Prognostic implications of RBD: risk disclosure and progression of the disease
Research advances in the field of RBD and neurodegeneration
Format
This in-person symposium brings international and national experts, and patient advocates, to present lectures, case studies, research updates, round tables, and interactive Q&A sessions.
Who should attend
This one-day symposium is ideal for those working with patients that present with sleep-related complaints and are interested in expanding their knowledge on RBD as a sleep condition with particular long-term implications. This includes, but is not limited to, sleep medicine and neurology consultants, GPs, specialist registrars, clinical psychologists, sleep technologists, clinical nurse specialists, and clinical pharmacists.
The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options.
Bial is an innovative international company with its own, globally-marketed medicines, and is a key player in Portuguese business, industry and biomedical research. Bial was the first and is still the only pharmaceutical company in Portugal with medicines that it has developed itself, and with nationally patented medicines on the market. In recent years, on average, Bial has funnelled more than 20% of its annual turnover towards R&D, which is focused on neuroscience and rare diseases.
Independent Physiological Diagnostics (IPD) specialises in sleep, respiratory and neurophysiological diagnostic testing across the UK. Our innovative domiciliary testing model offers patients the convenience of undergoing complex studies in the comfort of their own homes, catering to both paediatric and adult patients. At IPD, we are transforming sleep diagnostic pathways, bridging the gap between diagnosis and treatment. Our team of expert clinical physiologists combines technical expertise with a deep understanding of patient needs, ensuring a stress-free, personable, and seamless diagnostic experience.
We’re here to create positive change in the lives of patients and their families by bringing together expertise and excellence from 5 of London’s world-renowned hospitals, giving you access to exceptional specialist care.
Each of our hospitals – Evelina London Children’s, Guy’s, Harefield, Royal Brompton and St Thomas’ – are internationally recognised for their specialisms. Collaborating as a service, we lead the way in treating the world’s most complex cases – from before birth to later in life.
Doctors around the globe refer patients to us, recognising our distinguished specialisms in complex and diverse areas including heart and lung care, surgery, diagnostics, and women and children’s health.
Working closely together, our consultants and hospitals bring you personalised, multidisciplinary private care, combining specialist services across our sites and sharing expertise in pioneering new ways. This is how we go above and beyond, helping to improve, extend and save lives.
Our consultants are at the forefront of international research, using world-first innovations and sharing their expertise and knowledge to help healthcare services across the world evolve and flourish.
We’re also proud to be part of the NHS. Our profits are reinvested back into our NHS Trust to help create a bright future for healthcare in Britain and beyond.
Bioprojet UK Limited is the UK affiliate of Bioprojet PHARMA a French privately owned
pharmaceutical company headquartered in Paris founded in June 1982, dedicated to
the development, manufacturing, and supply of medicines throughout the
world. Bioprojet’s teams are guided in their mission by strong values: Innovation,
Integrity, Excellence, Passion, and Commitment in service of Science & Health for
patients.
The company engages in primary research and is focussed mainly on the areas of sleep,
allergy and anaphylaxis. In addition to the products wholly developed by Bioprojet the
company has licensed and acquired a variety of medicines to broaden its portfolio.
In sleep Bioprojet brought a novel 1st in class medicine, from research to market in the
UK and many other countries.
You can find out more about Bioprojet at our UK Website: www.Bioprojet.uk
If you require further information about Bioprojet products, please contact Medical
information in the 1st instance on 0330 1003684
Nyxoah is a medical technology company dedicated to developing and commercializing innovative solutions to treat Obstructive Sleep Apnoea (OSA). The company’s solution platform is based on the Genio® system, a user-centred, bilateral neurostimulation therapy designed to treat moderate to severe OSA with or without Complete Concentric Collapse (CCC). Both 1.5 & 3 Tesla MRI conditional the system offers a comfortable, mask-free alternative for patients unable to tolerate CPAP therapy. Genio® empowers patients to enjoy restful sleep and an improved quality of life.
